Remove Production Remove Protein Remove Research
article thumbnail

World Psoriasis Day 2024: New Treatments and Research Trends

XTalks

Trends in Psoriasis Research: Biologics, Biosimilars and New Therapies Recent innovations in biologics and biosimilars have transformed psoriasis care. Meanwhile, Innovent Biologics recently saw its New Drug Application (NDA) for picankibart, an IL-23p19 inhibitor, accepted by the Chinese National Medical Products Administration (NMPA).

Research 105
article thumbnail

Sanofi and Queensland collaborate to build $190m research facility

Pharmaceutical Technology

Sanofi has signed an agreement with the Queensland Government in Australia to establish a $190m (A$280m) research facility in Brisbane. The hub will connect Queensland scientists with the teams at Sanofi’s mRNA Centre of Excellence in the US and France, putting them at the front of international vaccine development and biomedical research.

Research 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How epilepsy researchers are moving the needle past anti-seizure treatments

Pharmaceutical Technology

While several therapeutics are available for treating symptoms associated with epilepsy, researchers and patients have strongly called out the need for more holistic treatments that would address the condition as a whole. Meanwhile, others are researching the link between gene variation and different responses to treatments.

Research 264
article thumbnail

Key Parkinson’s protein could offer new potential targets for treatment

Pharma Times

Researchers from Johns Hopkins University School of Medicine have revealed new findings about a key pathological protein associated with Parkinson’s disease (PD), which could lead to new treatments. However, its relation to dopaminergic neuron death is unclear.

Protein 122
article thumbnail

Beverage & Food IPOs in 2025: Companies Taking the Public Leap

XTalks

In 2025, new initial public offerings (IPOs) are emerging across packaged foods, alternative proteins and tech-enabled food solutions, signaling that scientific investment is becoming a key competitive differentiator. Below is a look at recent beverage and food IPOs of 2025. In February 2025, the company raised approximately $1.14

Packaging 105
article thumbnail

Gilead Sciences to exclusively license Nurix Therapeutics’ protein degrader

Pharmaceutical Technology

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. Additionally, Nurix will receive up to low double-digit tiered royalties on the net sales of the product.

Protein 130
article thumbnail

Astellas and Cullgen to develop small molecule protein degraders

Pharmaceutical Technology

Japan-based Astellas Pharma has entered a partnership with Cullgen to discover and develop multiple targeted protein degraders through the latter’s proprietary uSMITE targeted protein degradation platform, in a deal potentially worth $1.9bn. This method can target enzymes, transcription factors, scaffold proteins and more.

Protein 130